kyoyeonip

Notifications

Back

Notification settings

Back

Post notifications

Be notified when someone leaves a comment or a reply to your post or comment.

Updates and news

Stay ahead of important updates and news from the site.

Alarm
My account Sign out

한국어
English

VISION

SPECIALISTS

COLUMN

CONTACT

한국어
English

한국어
English

Mission

IP prosecution

- Represented by Experts in the fields of Chemistry, Biotech, and Pharmaceuticals

- Processed through direct and active communication with client

- Solve problems in advance through critical thinking

- Securing an appropriate scope of claims based on products

Our successes

Chong Kun Dang

HDAC6 inhibitors
CETP inhibitors
Liquid Crystal DDS platform
Vascular Disrupting Agent(VDA)
Robeglitazone (KR New Drug No.20)

Chong Kun Dang HDAC6 inhibitors
CETP inhibitors
Liquid Crystal DDS platform
Vascular Disrupting Agent(VDA)
Robeglitazone (KR New Drug No.20)

Boryung Pharmaceutical

PPAR-γ inhibitors
Donepezil DDS
Fimasartan(KR New Drug No.15)

Boryung Pharmaceutical PPAR-γ inhibitors
Donepezil DDS
Fimasartan(KR New Drug No.15)

ST Pharm

Tankyrase inhibitors
HIV integrase inhibitors
Oral Heparin DDS
mRNA Platform
Oligonucleotide preparation method

ST Pharm Tankyrase inhibitors
HIV integrase inhibitors
Oral Heparin DDS
mRNA Platform
Oligonucleotide preparation method

VORONOI

Tyrosine kinase inhibitors
Target protein degraders(TPD)

VORONOITyrosine kinase inhibitors
Target protein degraders(TPD)

UPPTHERA

Target protein degraders(TPD)

UPPTHERATarget protein degraders(TPD)

PINOTBIO

Antibody-drug conjugates(ADC)-

PINOTBIOAntibody-drug conjugates(ADC)-

ABLbio

Bispecific antibody

ABLbioBispecific antibody

DGMIF

CETP inhibitors
Tgase2 inhibitors

DGMIFCETP inhibitors
Tgase2 inhibitors

Kyoyeonip│2nd floor, 13, Teheran-ro 70-gil, Gangnam-gu, Seoul, 06194 Republic of Korea │Tel : +82-2-418-5282│ link@kyoyeonip.com

Copyright ⓒ 2021.Kyoyeonip.All rights reserved.